NMC
TCRX icon

Nine Masts Capital’s TScan Therapeutics TCRX Stock Holding History

Nine Masts Capital’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,740
Closed -$42.2K – 289
2026
Q1 		$42.2K Buy
+41,740
New +$44.6K 0.01% 168

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Nine Masts Capital's TCRX Position: Q2 2026 in Review

Nine Masts Capital sold out of TScan Therapeutics (TCRX) in Q2 2026, closing a stake of 41,740 shares — an estimated $42.2K sold.

Nine Masts Capital first reported a position in TCRX in Q1 2026 and held it in 1 quarter. The position peaked at $42.2K in Q1 2026. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Nine Masts Capital reported no remaining TScan Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 41,740 TScan Therapeutics shares in Q2 2026, an estimated $42.2K.
  • Nine Masts Capital first reported a position in TScan Therapeutics in Q1 2026 and held it in 1 quarter.
  • Nine Masts Capital's TScan Therapeutics position peaked at $42.2K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.